Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month improvement in median overall survival in patients treated with.
Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.
Nearly three-fourths of patients with clear cell renal cell carcinoma had a disease response lasting 12 months or longer after being treated with Welireg and Lenvima, study data showed.